| pubmed-article:19660004 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C1457887 | lld:lifeskim |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C0004096 | lld:lifeskim |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C0020846 | lld:lifeskim |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C0700624 | lld:lifeskim |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C0851347 | lld:lifeskim |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C2887459 | lld:lifeskim |
| pubmed-article:19660004 | lifeskim:mentions | umls-concept:C0966225 | lld:lifeskim |
| pubmed-article:19660004 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19660004 | pubmed:dateCreated | 2009-8-7 | lld:pubmed |
| pubmed-article:19660004 | pubmed:abstractText | Omalizumab, a subcutaneously administered anti-IgE antibody, is effective for moderate-to-severe persistent allergic asthma. The aims were to (i) describe the population pharmacodynamics of free IgE with a mechanism-based, nonlinear, omalizumab-IgE binding model; (ii) deduce a target-free IgE suppression level by correlation with clinical outcomes; and (iii) check the adequacy of current approved dosing tables and explore potential doses and regimens beyond. | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19660004 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19660004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19660004 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19660004 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:19660004 | pubmed:issn | 1365-2125 | lld:pubmed |
| pubmed-article:19660004 | pubmed:author | pubmed-author:JimenezPabloP | lld:pubmed |
| pubmed-article:19660004 | pubmed:author | pubmed-author:LowePhilip... | lld:pubmed |
| pubmed-article:19660004 | pubmed:author | pubmed-author:TannenbaumSta... | lld:pubmed |
| pubmed-article:19660004 | pubmed:author | pubmed-author:GautierAureli... | lld:pubmed |
| pubmed-article:19660004 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19660004 | pubmed:volume | 68 | lld:pubmed |
| pubmed-article:19660004 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19660004 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19660004 | pubmed:pagination | 61-76 | lld:pubmed |
| pubmed-article:19660004 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:meshHeading | pubmed-meshheading:19660004... | lld:pubmed |
| pubmed-article:19660004 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19660004 | pubmed:articleTitle | Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. | lld:pubmed |
| pubmed-article:19660004 | pubmed:affiliation | Novartis Pharma AG, Lichtstrasse 35, Basel, Switzerland. phil.lowe@novartis.com | lld:pubmed |
| pubmed-article:19660004 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19660004 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19660004 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19660004 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19660004 | lld:pubmed |
